Lenalidomide CAS No.191732-72-6
Product Name: Lenalidomide
Full English
name:(3S)-3-(4-Amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione
Chemical name: (3S) - 3 -
(4-amino-1-oxo-1,3-dihydro-2h-isoindole-2-yl) piperidine-2,6-dione;
(3S) - 3 - (4-amino-1-oxo-2-isoindolin) piperidine-2,6-dione
CAS No:191732-72-6
Molecular formula : C13H13N3O3
Molecular weight : 259.26062
Physical and chemical properties:
Melting point 269-271 ° C, density 1.460 ± 0.06 g / cm3.
Product category:
Lenalidomide is an anti-tumor drug developed by celgene
biopharmaceutical company in the United States. Its chemical
structure is similar to thalidomide, and it has multiple functions
such as anti-tumor, immune regulation and anti angiogenesis. It can
inhibit the secretion of pro-inflammatory cytokines and increase
the secretion of anti-inflammatory cytokines of peripheral blood
monocytes. In vitro experiments showed that the product could
inhibit the proliferation of some cell lines such as Namalwa cells.
Lenalidomide can inhibit the growth of multiple myeloma cells and
MM1S cells. In addition, the product can also inhibit the
expression of cyclooxygenase 2 (COX-2), but has no effect on COX-1.
Two multicenter, randomized, blind, placebo-controlled clinical
studies evaluated the safety and efficacy of lenalidomide in the
treatment of multiple myeloma. The main outcome of the study was
the mid-term analysis of TTP. The results showed that TTP in the
combination group was significantly superior to that in the
dexamethasone group. Recent clinical studies have shown that
lenalidomide can be used in the treatment of MDS and mm as well as
myeloma, leukemia, metastatic renal cancer, solid tumor, primary
systemic amyloidosis and systemic myelofibrosis with
myelometaplasia. Lenalidomide is a new generation derivative of
thalidomide, but it has not been found that it has teratogenic
toxicity, and its efficacy is 100 times stronger than thalidomide.
According to the results of phase III clinical trials, lenalidomide
is the most effective drug in the treatment of multiple myeloma.
More than half of the patients can prolong their survival time to
more than 3 years after taking the drug. In addition, it is also
the only drug that can effectively treat myelodysplastic syndrome
(MDS). Clinical results show that 64% of MDS patients use
naduramine to treat MDS without blood transfusion.
